Suchergebnisse
Suchergebnisse:
Vor 2 Tagen · Partner. Silicon Valley. +1 650 752 3422. San Francisco. View PDF. Andrew is a partner in Goodwin’s Technology group. He provides strategic counseling to emerging and high-growth companies on matters spanning the entire corporate lifecycle, including pre-incorporation planning, corporate governance, venture capital financings, joint ventures ...
Vor einem Tag · Andrew Harper has joined Goodwin Procter as a partner with the firm’s technology and climate tech practices in Silicon Valley, the firm said Monday. Harper counsels emerging and high-growth companies on the corporate lifecycle, including pre-incorporation planning, corporate governance, venture capital financings, joint ventures, M&A, and ...
Vor 10 Stunden · United States. Global law firm Goodwin announced today the addition of Andrew Harper as a Silicon Valley -based partner in the firm's Technology and Climate Tech practices. "Andrew is a highly-regarded emerging companies and venture capital lawyer who brings to Goodwin a practice that aligns perfectly with our strategic objectives", said Craig ...
Vor einem Tag · This post comes to us from Goodwin Procter LLP. It is based on the firm’s memorandum, “Equity on Ice: A Solution for the Repurchase Conundrum,” dated May 7, 2024, and available here. One of the keys of successful private equity investing is properly aligning the economic incentives and interests of the sponsor and its portfolio companies ...
Vor 5 Tagen · Explore the acquisition of Proteologix by Johnson & Johnson for $850 million, including the potential for milestone payments, and the innovative bispecific antibody programs ready to transform treatment for various diseases.
Vor 5 Tagen · Goodwin Procter has brought in private investment funds partner Virginie Leroy for its growing office in Luxembourg. She arrives from Benelux firm AKD, where she was a partner and co-head of...
Vor 5 Tagen · Learn about the research collaboration between Novo Nordisk and Metaphore Biotechnologies, Inc., utilizing the MIMIC™ platform for innovative multitarget therapeutics in obesity management, supported by Flagship Pioneering's bioplatform expertise.
